Journal of Clinical Oncology
Articles in this Issue
Clinicopathological characteristics of patients with minimal residual disease in stage II–III colon cancer: Interim results from the observational cohort of CLAUDIA study.
3635 Background: Circulating tumor DNA (ctDNA) monitoring for minimal residual disease (MRD) has emerged as a key prognost...
Integrin α <sub>v</sub> β <sub>3</sub> -targeted radionuclide therapy with <sup>177</sup> Lu-AB-3PRGD <sub>2</sub> in multiple advanced metastatic solid tumors: A prospective, single-arm, single-center, investigator-initiated clinical trial.
3009 Background: Tumor angiogenesis drives progression and metastasis in solid malignancies. Integrin α...
Evaluation of dietary habits and lifestyle in patients with bone sarcoma: Pilot study results of the Italian Metabol Sarc study (NCT04735289).
e23503 Background: Dietary behavior, lifestyle, and metabolic alterations such as obesity and insulin resistance are well...
Predicting 12-month overall survival from response rate and 6-month progression-free survival in oncology clinical trials: An embedding-based machine learning approach.
e13667 Background: Overall Survival (OS) remains the regulatory gold standard endpoint, but early trial decisions depend o...
Taxane and platinum combination as a predictor of pathologic complete response in I-SPY2 by gene expression breast cancer signatures.
608 Background: Carboplatin is part of NCCN-preferred neoadjuvant chemotherapy (NAC) for stage II-III triple negative (TN)...
Efficacy and safety of pralsetinib as first-line treatment of <i>RET</i> fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
8504 Background: Pralsetinib, an oral tyrosine kinase inhibitor, selectively and potently targets oncogenic...
Empegfilgrastim for primary febrile neutropenia prophylaxis during induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in head and neck squamous cell carcinoma.
e18030 Background: Induction chemotherapy (CT) with docetaxel, cisplatin, and 5fluorouracil (DCF) before chemoradiotherapy...
Real-world overall survival with mirvetuximab soravtansine compared with chemotherapy after multiple lines of platinum therapy in gynecologic cancers.
e17567 Background: Mirvetuximab soravtansine (MIRV) is FDA-approved for FRα-high, platinum-resistant ovarian cancer, with...
Deep learning–based classification of benign and malignant breast lesions on ultrasound using knowledge distillation with external validation and global deployment.
556 Background: Breast cancer is the most common malignancy in women worldwide. Although breast ultrasonography is widely...
Extracellular matrix-derived liquid biopsy for predicting response in patients with biliary tract cancer treated with nivolumab with or without ipilimumab combined with stereotactic body radiotherapy: Insights from the CheckPAC trial.
3043 Background: Biliary tract cancer (BTC) is a rare malignancy with limited treatment options and poor prognosis. Althou...
TAMS in appendiceal cancer: Association with metabolic remodeling, prognosis, and response to intra-tumoral therapy.
3597 Background: Appendiceal cancer (AC) is a rare malignancy with a distinct immunobiology and propensity for peritoneal...
Implementing targeted thromboprophylaxis as a supportive care model: Mapping implementation preferences across the cancer care pathway.
e13552 Background: Risk-directed supportive care models aim to target interventions to patients most likely to benefit, ye...
Comparative analysis of depression, anxiety, suicidality, substance use, and palliative care use in pain-afflicted multiple myeloma patients across White, Black, and Hispanic populations.
e19501 Background: Bone pain affects 93% of multiple myeloma (MM) patients, significantly impairing quality of life and tr...
Long-term follow-up of satricabtagene autoleucel (satri-cel) as sequential therapy after first-line treatment for advanced gastric cancer: A subgroup analysis.
2557 Background: Claudin18.2 (CLDN18.2) has emerged as a new target for the treatment of gastric cancer in the first-line...
Descriptive comparison of primary debulking surgery (PDS-ACT) versus neoadjuvant chemotherapy with interval debulking (NACT-IDS) in stage III–IV epithelial ovarian cancer: Single-center experience.
e17598 Background: Optimal cytoreduction remains a cornerstone of management for advanced epithelial ovarian cancer (EOC)....
PROPEL: Capturing the lived experience of lung cancer for patients and caregivers.
e23255 Background: A limited understanding of the lived experience of a lung cancer diagnosis hinders the development of a...
Representing people's experience of cancer and its treatment (ResPECT) pilot study: A global collaborative study to improve cancer care and outcomes as part of the Lancet Commission on Cancer and Health Systems.
1592 Background: Measurement of cancer burden increasingly informs survivorship research, health system design, and policy...
Optimizing biliary drainage in malignant biliary obstruction: A systematic review and meta-analysis of transpapillary versus suprapapillary stent positioning.
4155 Background: Malignant biliary obstruction causes significant morbidity and poor survival with 5-year survival rates b...
Automated abstraction of colorectal cancer registry data using AI: Accuracy and implementation insights.
e15516 Background: Cancer registries support surveillance, quality measurement, and research, yet abstraction of high-valu...
Adjuvant and neoadjuvant evaluation of a structural variant-based MRD assay in early breast cancer: A real-world cohort.
e12607 Background: Despite curative intent surgery and standard adjuvant therapy, patients (pts) with ER+, node+ stage II–...
A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.
TPS3180 Background: Mitochondria are subcellular organelles whose signaling and bioenergetics functions are exploited in c...
Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory <i>FLT3</i> -mutated AML.
6504 Background: Hypomethylating agents (HMAs; azacitidine/decitabine) plus venetoclax (VEN) are standard for newly diagno...
Spatial transcriptomic profiling to identify stroma-based prognostic groups in oncogene-addicted lung cancer.
8611 Background: Driver genomic aberrations determine prognosis and therapy in non-small cell lung cancer (NSCLC). In this...
Assessing treatment patterns and outcomes among patients (pts) with metastatic renal cell carcinoma (mRCC): A British Columbia (BC) population-based analysis.
e16544 Background: Current first-line treatments for mRCC include immune check point inhibitors (IO) and tyrosine kinase i...
Gaps in access to chimeric antigen receptor T-cell (CAR-T) therapy post leukapheresis: Waiting time and post-leukapheresis treatment patterns in relapsed/refractory multiple myeloma (RRMM)—Real-world evidence from U.S. claims.
7530 Background: B-cell maturation antigen (BCMA)-directed CAR-T therapy is a highly effective treatment with potential fo...